139 related articles for article (PubMed ID: 3719056)
1. Testing for a treatment effect in the presence of nonresponders.
Boos DD; Brownie C
Biometrics; 1986 Mar; 42(1):191-7. PubMed ID: 3719056
[TBL] [Abstract][Full Text] [Related]
2. Investigating maximum power losses in survival studies with nonstratified randomization.
Palta M
Biometrics; 1985 Jun; 41(2):497-504. PubMed ID: 4027324
[TBL] [Abstract][Full Text] [Related]
3. A SAS macro for sample size adjustment and randomization test for internal pilot study.
Wang S; Xia J; Yu L; Li C; Xu L
Comput Methods Programs Biomed; 2008 Apr; 90(1):66-88. PubMed ID: 18192069
[TBL] [Abstract][Full Text] [Related]
4. [Randomization for controlled therapeutic trials].
Schemper M
Wien Klin Wochenschr; 1982 Nov; 94(22):604-9. PubMed ID: 7164464
[TBL] [Abstract][Full Text] [Related]
5. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
Kim K; Boucher H; Tsiatis AA
Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials:randomization before consent.
Armstrong PW; Watts DG
Biomedicine; 1981 Sep; 34(2):65-6. PubMed ID: 7284544
[TBL] [Abstract][Full Text] [Related]
7. Group sequential t-test for clinical trials with small sample sizes across stages.
Shao J; Feng H
Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
[TBL] [Abstract][Full Text] [Related]
8. Randomization and efficiency in Zelen's single-consent design.
Matts J; McHugh R
Biometrics; 1987 Dec; 43(4):885-94. PubMed ID: 3427173
[TBL] [Abstract][Full Text] [Related]
9. On design considerations and randomization-based inference for community intervention trials.
Gail MH; Mark SD; Carroll RJ; Green SB; Pee D
Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140
[TBL] [Abstract][Full Text] [Related]
10. A note on the operating characteristics of the modified F test.
Blair RC; Sawilowsky S
Biometrics; 1993 Sep; 49(3):935-9. PubMed ID: 8241380
[TBL] [Abstract][Full Text] [Related]
11. The relative efficiency of Zelen's prerandomization design for clinical trials.
Anbar D
Biometrics; 1983 Sep; 39(3):711-8. PubMed ID: 6652204
[TBL] [Abstract][Full Text] [Related]
12. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
Ayanlowo AO; Redden DT
Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
[TBL] [Abstract][Full Text] [Related]
13. Varying cluster sizes in trials with clusters in one treatment arm: sample size adjustments when testing treatment effects with linear mixed models.
Candel MJ; Van Breukelen GJ
Stat Med; 2009 Aug; 28(18):2307-24. PubMed ID: 19472169
[TBL] [Abstract][Full Text] [Related]
14. A note on one-sided tests with multiple endpoints.
Perlman MD; Wu L
Biometrics; 2004 Mar; 60(1):276-9; discussion 279-80. PubMed ID: 15032799
[TBL] [Abstract][Full Text] [Related]
15. Sequential monitoring of randomization tests: stratified randomization.
Zhang Y; Rosenberger WF; Smythe RT
Biometrics; 2007 Sep; 63(3):865-72. PubMed ID: 17825016
[TBL] [Abstract][Full Text] [Related]
16. The B-value: a tool for monitoring data.
Lan KK; Wittes J
Biometrics; 1988 Jun; 44(2):579-85. PubMed ID: 3390511
[TBL] [Abstract][Full Text] [Related]
17. Nonparametric tests for comparing umbrella pattern treatment effects with a control in a randomized block design.
Lim DH; Wolfe DA
Biometrics; 1997 Jun; 53(2):410-8. PubMed ID: 9235118
[TBL] [Abstract][Full Text] [Related]
18. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
Atkinson AC; Biswas A
Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
[TBL] [Abstract][Full Text] [Related]
19. Designing for cancer clinical trials: selection of prognostic factors.
Brown BW
Cancer Treat Rep; 1980; 64(2-3):499-502. PubMed ID: 7407790
[TBL] [Abstract][Full Text] [Related]
20. Group sequential clinical trials with triangular continuation regions.
Whitehead J; Stratton I
Biometrics; 1983 Mar; 39(1):227-36. PubMed ID: 6871351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
